Search results
Results from the WOW.Com Content Network
Lanreotide, sold under the brand name Somatuline among others, is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin , like octreotide .
These are combined with indium-111, lutetium-177 or yttrium-90 for treatment. [5] 111 In is primarily used for imaging alone, however in addition to its gamma emission there are also Auger electrons emitted, which can have a therapeutic effect in high doses. [6] 90 Y is bound with DOTATOC for PRRT treatments. The natural somatostatin receptor ...
Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary to neuroendocrine tumors (formerly known as carcinoid tumors). [1] The syndrome is caused by neuroendocrine tumors most often found in the gut releasing biologically active substances into the blood causing symptoms such as flushing and diarrhea, and less frequently, heart failure, vomiting ...
It is indicated for symptomatic treatment of carcinoid syndrome and acromegaly. [ 22 ] [ 23 ] It is also finding increased use in polycystic diseases of the liver and kidney. Lanreotide (Somatuline, Ipsen Pharmaceuticals ) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid ...
Treatments have improved over the past several decades, and outcomes are improving. [49] In malignant carcinoid tumors with carcinoid syndrome, the median survival has improved from two years to more than eight years. [75] Detailed guidelines for managing neuroendocrine tumors are available from ESMO, [76] NCCN [77] and a UK panel. [1]
A carcinoid (also carcinoid tumor) is a slow-growing [1] type of neuroendocrine tumor originating in the cells of the neuroendocrine system. In some cases, metastasis may occur. Carcinoid tumors of the midgut ( jejunum , ileum , appendix , and cecum ) are associated with carcinoid syndrome .
A small intestine neuroendocrine tumor is a carcinoid in the distal small intestine or the proximal large intestine. It is a relatively rare cancer and is diagnosed in approximately 1/100000 people every year. In recent decades the incidence has increased. [1]
The foundation was founded in 2004 by Nancy Lindholm (formerly Nancy O'Hagan), who was a carcinoid patient. [ 6 ] [ 7 ] It is located in Boston. [ 8 ] On November 10, 2010, the foundation celebrated the first annual Worldwide Neuroendocrine Tumor (NET) Cancer Awareness Day by launching their new website, which provides comprehensive information ...